ERGO Stock Overview
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£10.58|
|52 Week High||UK£15.85|
|52 Week Low||UK£9.25|
|1 Month Change||-17.86%|
|3 Month Change||-3.82%|
|1 Year Change||-13.98%|
|3 Year Change||376.58%|
|5 Year Change||417.36%|
|Change since IPO||551.08%|
Recent News & Updates
|ERGO||GB Life Sciences||GB Market|
Return vs Industry: ERGO exceeded the UK Life Sciences industry which returned -42.9% over the past year.
Return vs Market: ERGO underperformed the UK Market which returned -2.7% over the past year.
|ERGO Average Weekly Movement||8.2%|
|Life Sciences Industry Average Movement||9.7%|
|Market Average Movement||6.0%|
|10% most volatile stocks in GB Market||11.6%|
|10% least volatile stocks in GB Market||3.1%|
Stable Share Price: ERGO is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ERGO's weekly volatility (8%) has been stable over the past year.
About the Company
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies.
Ergomed Fundamentals Summary
|ERGO fundamental statistics|
Is ERGO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ERGO income statement (TTM)|
|Cost of Revenue||UK£52.19m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.26|
|Net Profit Margin||10.69%|
How did ERGO perform over the long term?See historical performance and comparison
Is Ergomed undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ERGO (£10.58) is trading below our estimate of fair value (£24.17)
Significantly Below Fair Value: ERGO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ERGO is good value based on its Price-To-Earnings Ratio (41.3x) compared to the European Life Sciences industry average (45.7x).
PE vs Market: ERGO is poor value based on its Price-To-Earnings Ratio (41.3x) compared to the UK market (15.4x).
Price to Earnings Growth Ratio
PEG Ratio: ERGO is poor value based on its PEG Ratio (2.8x)
Price to Book Ratio
PB vs Industry: ERGO is overvalued based on its Price-To-Book Ratio (7.8x) compared to the GB Life Sciences industry average (3.1x).
How is Ergomed forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ERGO's forecast earnings growth (14.8% per year) is above the savings rate (0.9%).
Earnings vs Market: ERGO's earnings (14.8% per year) are forecast to grow faster than the UK market (11.3% per year).
High Growth Earnings: ERGO's earnings are forecast to grow, but not significantly.
Revenue vs Market: ERGO's revenue (12.7% per year) is forecast to grow faster than the UK market (4% per year).
High Growth Revenue: ERGO's revenue (12.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ERGO's Return on Equity is forecast to be high in 3 years time
How has Ergomed performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ERGO has a large one-off loss of £4.7M impacting its December 31 2021 financial results.
Growing Profit Margin: ERGO's current net profit margins (10.7%) are lower than last year (11.2%).
Past Earnings Growth Analysis
Earnings Trend: ERGO has become profitable over the past 5 years, growing earnings by 59.7% per year.
Accelerating Growth: ERGO's earnings growth over the past year (30.9%) is below its 5-year average (59.7% per year).
Earnings vs Industry: ERGO earnings growth over the past year (30.9%) underperformed the Life Sciences industry 50.8%.
Return on Equity
High ROE: ERGO's Return on Equity (18.8%) is considered low.
How is Ergomed's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ERGO's short term assets (£60.3M) exceed its short term liabilities (£35.4M).
Long Term Liabilities: ERGO's short term assets (£60.3M) exceed its long term liabilities (£3.4M).
Debt to Equity History and Analysis
Debt Level: ERGO is debt free.
Reducing Debt: ERGO had no debt 5 years ago.
Debt Coverage: ERGO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ERGO has no debt, therefore coverage of interest payments is not a concern.
What is Ergomed current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ERGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ERGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ERGO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ERGO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ERGO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ergomed has no CEO, or we have no data on them.
Experienced Management: ERGO's management team is considered experienced (2.9 years average tenure).
Experienced Board: ERGO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ergomed plc's employee growth, exchange listings and data sources
- Name: Ergomed plc
- Ticker: ERGO
- Exchange: AIM
- Founded: 1997
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£529.860m
- Shares outstanding: 49.52m
- Website: https://www.ergomedplc.com
Number of Employees
- Ergomed plc
- Surrey Research Park
- 1 Occam Court
- GU2 7HJ
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.